|
Jan 4
|
Better Buy: Novo Nordisk vs. AstraZeneca
|
|
Jan 3
|
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
|
|
Jan 3
|
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
|
|
Jan 2
|
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
|
|
Jan 2
|
5 Large Drug Stocks to Keep An Eye On in the New Year
|
|
Dec 30
|
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Champions for 2024?
|
|
Jul 18
|
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
|
|
Jul 18
|
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
|
|
Jul 17
|
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
|
|
Jul 16
|
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
|
|
Jul 16
|
AstraZeneca completes Amolyt Pharma acquisition
|
|
Jul 15
|
AstraZeneca’s Tagrisso gains approval in Canada for NSCLC
|
|
Jun 26
|
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
|
|
Jun 26
|
Novo Nordisk, Eli Lilly still top 2 pharma stocks: Analyst
|
|
Jun 26
|
China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
|
|
Jun 26
|
AstraZeneca’s Tagrisso receives approval in Japan for lung cancer
|
|
Jun 25
|
Health Care Roundup: Market Talk
|
|
Jun 25
|
AstraZeneca makes another obesity play funnelling $80m into SixPeaks Bio
|
|
Jun 25
|
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
|
|
Jun 25
|
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
|